Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Drug 1
Drug · 1 trial · 1 indication
To investigate the effects of GSK1034702 on the mismatch negativity neurophysiologic marker of cognition.
| Arm | Type | Description |
|---|---|---|
| Study drug at 4mg | EXPERIMENTAL | GSK1034702 at 4mg |
| Study drug at 8mg | EXPERIMENTAL | GSK1034702 at 8mg |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Drug | DRUG | Placebo |
Inclusion Criteria A subject will be eligible for inclusion in this study only if all of the following criteria apply: * Otherwise healthy smokers as determined by a responsible physician, based on a medical evaluation including own and familial medical history, physical examination, psychiatric hi...
Drug is an investigational small molecule being studied for use in mental disorders. It is in Phase 1 clinical development, with a completed trial that examined its pharmacodynamic effects on neurophysiological biomarkers of cognition in nicotine abstained otherwise healthy smokers.
Drug is being developed by GSK plc, a pharmaceutical company traded on the stock exchange under the ticker GSK. The company is conducting clinical research on this investigational small molecule for mental disorders.
Drug is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It is not approved by regulatory authorities and is still undergoing clinical research.
Drug has one completed clinical trial, identified as NCT01371799. This Phase 1 study examined the pharmacodynamic effects of Drug on neurophysiological biomarkers of cognition in nicotine abstained otherwise healthy smokers. The trial enrolled 9 male participants in the United Kingdom.
Yes, Drug is also known as Drug 1. Both names refer to the same investigational small molecule being developed by GSK plc for mental disorders.
The completed Phase 1 trial for Drug was randomized, double-blind, and placebo-controlled. It enrolled 9 healthy male volunteers aged 18 years and older in the United Kingdom, and the study has been completed.